News: Host-Tumor Interactions Research Program

Ann Richmond, PhD, Ingram Professor of Cancer Research, is the 2019 recipient of the Society for Leukocyte Biology Legacy Award.

GE Healthcare has awarded researchers $2.5 million in funding to develop PET tracer that will determine the effectiveness of immunotherapy in patients early in their treatment course.

Jeffrey Rathmell, PhD, is a 2019 recipient of the Dr. William E. Paul Distinguished Innovator Award in Lupus and Autoimmunity.

Two Vanderbilt-Ingram Cancer Center investigators have received financial support from Susan G. Komen for breast cancer research.

A study led by Anna Vilgelm, MD, PhD, and Ann Richmond, PhD, has identified a possible second-line treatment for melanoma patients.

A previously unrecognized role for a cell surface receptor may open new therapeutic options for the treatment of fibrotic diseases.

The Vanderbilt Center for Immunobiology has relaunched its mission with a greater focus on human immunology, an endeavor supported by additional researchers, more funding support and designation as a Center of Excellence.

James Crowe Jr., MD, has been honored by the science and technology company Merck KGaA, Darmstadt, Germany for his contributions to developing new therapeutics and vaccines against some of the world’s deadliest viruses.

A study published June 17 in Nature offers clues as to why blocking inhibitory receptors on tumor-infiltrating T cells may not always work

John Gore, PhD, director of the Vanderbilt University Institute of Imaging Science (VUIIS), and Michael King, PhD, J. Lawrence Wilson Professor and chair of the Department of Biomedical Engineering at Vanderbilt University, were recently elected to the International Academy of Medical and Biological Engineering (IAMBE) 2019 Class of Fellows in recognition of their contributions in the field of medical and biological engineering.